Core Insights - Senti Biosciences, Inc. has appointed Bryan Baum to its Board of Directors, enhancing its leadership team with his extensive entrepreneurial and investment experience [1][3][4] - Bryan Baum is recognized for his successful track record in scaling companies and has invested in notable firms such as SpaceX, OpenAI, and Airbnb, which may provide strategic advantages to Senti Bio [2][3] - The company is focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, aiming to address cancer treatments that current drugs cannot [3][5] Company Overview - Senti Bio is a clinical-stage biotechnology company that leverages synthetic biology to engineer Gene Circuits for new medicines, targeting incurable diseases [5] - The company's pipeline includes cell therapies designed to specifically target and kill cancer cells while sparing healthy cells, with preclinical evidence supporting their efficacy in both NK and T cells [5] - Senti Bio is also exploring the potential of Gene Circuits in other disease modalities beyond oncology, indicating a broad scope for future development [5]

Key Takeaways LLY's tirzepatide drugs now drive 50% of revenues, with global demand fueling momentum. MRK relies heavily on Keytruda but faces headwinds in China and looming patent expirations. LLY forecasts up to 32% sales growth in 2025, while MRK's EPS and revenue estimates continue to decline.Both Eli Lilly (LLY) and Merck (MRK) are major players in the U.S. pharmaceutical industry, developing and commercializing therapies across oncology, immunology, and diabetes and cardiovascular areas. While Lilly ...

Abeona will receive a license payment and potential development, regulatory, and sales milestones, and royaltiesCLEVELAND, July 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, has exercised its option to license Abeona's patented AAV204 capsid for use in potential gene therapies for a range of prevalent and rare retinal diseases that result in blindness. This worldwide, non-exclus ...

Core Insights - Abeona Therapeutics Inc. has been added to the U.S. small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective June 30, 2025, marking a significant milestone for the company [1][2] - The inclusion in these indexes is expected to enhance the company's visibility and attract a wider range of investors, particularly following the FDA approval of ZEVASKYN™ [2] - The Russell 3000® Index includes the 3,000 largest U.S.-traded stocks, and membership is updated annually, providing a benchmark for investment strategies [3] Company Overview - Abeona Therapeutics is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases [4] - ZEVASKYN™ is the first autologous cell-based gene therapy approved for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB) [4] - The company operates a fully integrated cGMP manufacturing facility in Cleveland, Ohio, which is responsible for ZEVASKYN's commercial production [4]

SAN DIEGO, June 12, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the "Class Period"), have until August 11, 2025 to seek appointment as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. Captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.), the Rocket Pharmaceuticals class action lawsuit charges Rocket Pharmaceutica ...

Core Insights - Senti Biosciences, Inc. is participating in a Virtual Fireside Chat hosted by Chardan Capital Markets on June 9, 2025, featuring key executives discussing the company's advancements in biotechnology [1][2]. Company Overview - Senti Biosciences is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][3]. - The company aims to create therapies that can precisely target and kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing for controllability post-administration [3]. - Senti's pipeline includes cell therapies engineered with Gene Circuits targeting both liquid and solid tumors, with preclinical evidence supporting their efficacy in NK and T cells [3]. Additional Information - For further details, Senti Biosciences encourages stakeholders to visit their official website and follow their social media channels for updates and disclosures [4].

Core Insights - Pfizer has decided to discontinue the development of Danuglipron due to safety concerns and is now looking for business development opportunities to acquire promising product candidates [1] Group 1: Company Actions - Pfizer is actively seeking to acquire new product candidates following the halt of Danuglipron's development [1] Group 2: Analyst Background - The analyst has over 20 years of experience in research and development of novel Cell & Gene Therapies, focusing on assessing the potential of new treatments and their ability to generate shareholder returns [1]

Company Overview - Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases [3] - The company's flagship product, ZEVASKYN™ (prademagene zamikeracel), is the first and only autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB) [3] - Abeona operates a fully integrated cGMP manufacturing facility in Cleveland, Ohio, which is dedicated to the commercial production of ZEVASKYN [3] Upcoming Events - The CEO, Vish Seshadri, and the Chief Commercial Officer, Madhav Vasanthavada, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025, at 11:40 a.m. Eastern Time [1] - A live webcast of the event will be available on the Investors section of the Abeona website and will be archived for 30 days [2] Product Development - Abeona's development portfolio includes adeno-associated virus (AAV)-based gene therapies targeting ophthalmic diseases with significant unmet medical needs [3] - The company is evaluating next-generation AAV capsids to enhance tropism profiles for various severe diseases [3]

Company Overview - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [3] - The company aims to create new medicines that can precisely target and kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing for control even after administration [3] Upcoming Event - Timothy Lu, M.D., Ph.D., Co-Founder and CEO of Senti Bio, will present at the LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on May 29, 2025, at 2:40 PM ET [1][2] Technology and Pipeline - Senti Bio's pipeline includes cell therapies engineered with Gene Circuits targeting challenging liquid and solid tumor indications [3] - The Gene Circuits have shown preclinical efficacy in both NK and T cells, with potential applications extending beyond oncology [3]

Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025AstraZeneca partnership: R&D activities ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorderCellectis will present novel non-viral gene editing ...